Colorectal Cancer
Jan 30, 2025, 04:03
Overall survival by ctDNA status and clecoxib use in Colorectal Cancer
Keith Hanigan, Vice President Oncology Marketing at Natera, shared a post on LinkedIn:
“So many highlights from Natera at ASCO GI this weekend, including a successful readout of the 80702 trial in colorectal cancer.
Of note, Signatera-positive patients treated with both adjuvant chemotherapy and celecoxib showed a 40% improvement in overall survival versus chemotherapy alone. This marks an unprecedented moment in personalized medicine for patients with colorectal cancer.
Thank you to all involved in this first-of-its-kind study.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 30, 2025, 04:03
Jan 30, 2025, 03:48
Jan 30, 2025, 03:40
Jan 30, 2025, 03:06
Jan 29, 2025, 22:27
Jan 29, 2025, 22:26